Michelle Fung, Ka̅rlis Be̅rziņš, Raj Suryanarayanan
文献索引:10.1021/acs.molpharmaceut.8b00035
全文:HTML全文
In an earlier investigation, coamorphous systems of ketoconazole (KTZ) prepared with each oxalic (OXA), tartaric (TAR), citric (CIT), and succinic (SUC) acid, revealed drug–acid ionic or hydrogen bonding interactions in the solid-state (Fung et al, Mol. Pharmaceutics, 2018, 15 (3), 1052–1061). We showed that the drug–acid interactions in KTZ–TAR were the strongest, followed by KTZ–OXA, KTZ–CIT, and KTZ–SUC. In this study, we investigated the crystallization propensity and dissolution behavior of the KTZ–acid coamorphous systems. When in contact with water (either as water vapor or as aqueous phosphate buffer), while KTZ–CIT and KTZ–TAR were physically stable and resisted crystallization, KTZ–SUC and KTZ–OXA crystallized more readily than KTZ alone. The dissolution performances of the coamorphous systems were compared using the area under the curve (AUC) obtained from the concentration–time profiles. KTZ–OXA exhibited the highest AUC, while it was about the same for KTZ–TAR and KTZ–CIT and the lowest for KTZ–SUC. The enhancement in dissolution appeared to become more pronounced as the strength of the acid (OXA > TAR > CIT > SUC) increased. Coamorphization with acid caused at least a two-fold increase in AUC when compared with amorphous KTZ. The decrease in pH of the diffusion layer of the dissolving solid, brought about by the acid, is at least partially responsible for the dissolution enhancement. In addition, the particles of KTZ–OXA, KTZ–TAR, and KTZ–CIT were much smaller than those of KTZ–SUC. The consequent effect on surface area could be another contributing factor to the initial dissolution behavior.
Grapefruit Flavonoid Naringenin Regulates the Expression of ...
2018-04-19 [10.1021/acs.molpharmaceut.7b00797] |
A Triazole Disulfide Compound Increases the Affinity of Hemo...
2018-04-18 [10.1021/acs.molpharmaceut.8b00108] |
CysLTR1 Blockage Ameliorates Liver Injury Caused by Aluminum...
2018-04-16 [10.1021/acs.molpharmaceut.8b00121] |
Application of a Salt Coformer in a Co-Amorphous Drug System...
2018-04-13 [10.1021/acs.molpharmaceut.8b00174] |
Treatment of Canine Oral Melanoma with Nanotechnology-Based ...
2018-04-12 [10.1021/acs.molpharmaceut.8b00126] |
首页 |
期刊大全 |
MSDS查询 |
化工产品分类 |
生物活性化合物 |
关于我们 |
免责声明:知识产权问题请联系 service1@chemsrc.com
Copyright © 2024 ChemSrc All Rights Reserved